Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of tebapivat in sickle cell disease
NL-OMON60585Phase 2Active, not recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tebapivat in sickle cell disease (SCD) (3 arms), sponsored by Agios Pharmaceuticals. Primary endpoint: Hemoglobin response. Started Oct 2025; status: active, not recruiting.
02
Drugs
tebapivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NL-OMON60585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60585.